155 related articles for article (PubMed ID: 19814747)
1. Screening for hepatitis B in chemotherapy patients: survey of current oncology practices.
Tran TT; Rakoski MO; Martin P; Poordad F
Aliment Pharmacol Ther; 2010 Jan; 31(2):240-6. PubMed ID: 19814747
[TBL] [Abstract][Full Text] [Related]
2. Oncologists and hepatitis B: a survey to determine current level of awareness and practice of antiviral prophylaxis to prevent reactivation.
Khokhar OS; Farhadi A; McGrail L; Lewis JH
Chemotherapy; 2009; 55(2):69-75. PubMed ID: 19077421
[TBL] [Abstract][Full Text] [Related]
3. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies.
Lalazar G; Rund D; Shouval D
Br J Haematol; 2007 Mar; 136(5):699-712. PubMed ID: 17338776
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: precore/core mutations may play an important role.
Steinberg JL; Yeo W; Zhong S; Chan JY; Tam JS; Chan PK; Leung NW; Johnson PJ
J Med Virol; 2000 Mar; 60(3):249-55. PubMed ID: 10630955
[TBL] [Abstract][Full Text] [Related]
5. [Immunosuppressive therapy or chemotherapy-induced reactivation of hepatitis B virus infection].
Sato K
Gan To Kagaku Ryoho; 2011 Feb; 38(2):161-8. PubMed ID: 21368477
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study.
Yeo W; Chan PK; Hui P; Ho WM; Lam KC; Kwan WH; Zhong S; Johnson PJ
J Med Virol; 2003 Aug; 70(4):553-61. PubMed ID: 12794717
[TBL] [Abstract][Full Text] [Related]
7. Rheumatologists' awareness of and screening practices for hepatitis B virus infection prior to initiating immunomodulatory therapy.
Stine JG; Khokhar OS; Charalambopoulos J; Shanmugam VK; Lewis JH
Arthritis Care Res (Hoboken); 2010 May; 62(5):704-11. PubMed ID: 20461789
[TBL] [Abstract][Full Text] [Related]
8. [Hepatitis B reactivation following immunosuppressive therapy and screening adherence: a neglected problem?].
Borde JP; Kern WV; Becker J; Bertz H; Hübner J; Offensperger WB
Dtsch Med Wochenschr; 2012 Jul; 137(28-29):1458-62. PubMed ID: 22760404
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis B virus reactivation in patients receiving chemotherapy for malignancies: role of precore stop-codon and basic core promoter mutations.
Alexopoulou A; Theodorou M; Dourakis SP; Karayiannis P; Sagkana E; Papanikolopoulos K; Archimandritis AJ
J Viral Hepat; 2006 Sep; 13(9):591-6. PubMed ID: 16907845
[TBL] [Abstract][Full Text] [Related]
10. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy.
Yeo W; Chan PK; Ho WM; Zee B; Lam KC; Lei KI; Chan AT; Mok TS; Lee JJ; Leung TW; Zhong S; Johnson PJ
J Clin Oncol; 2004 Mar; 22(5):927-34. PubMed ID: 14990649
[TBL] [Abstract][Full Text] [Related]
11. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy.
Hui CK; Cheung WW; Zhang HY; Au WY; Yueng YH; Leung AY; Leung N; Luk JM; Lie AK; Kwong YL; Liang R; Lau GK
Gastroenterology; 2006 Jul; 131(1):59-68. PubMed ID: 16831590
[TBL] [Abstract][Full Text] [Related]
12. Fatal reactivation of hepatitis B virus in a patient who was hepatitis B surface antigen negative and core antibody positive before receiving chemotherapy for non-Hodgkin lymphoma.
Wu JM; Huang YH; Lee PC; Lin HC; Lee SD
J Clin Gastroenterol; 2009; 43(5):496-8. PubMed ID: 19247200
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis B reactivation in cancer patients: role of prechemotherapy screening and antiviral prophylaxis.
Kawsar HI; Shahnewaz J; Gopalakrishna KV; Spiro TP; Daw HA
Clin Adv Hematol Oncol; 2012 Jun; 10(6):370-8. PubMed ID: 22895238
[TBL] [Abstract][Full Text] [Related]
14. [A clinical analysis of HBV reactivation in patients with malignant tumors].
Ma LN; Sun GZ; Dong JL; Huang CY; Chen XY
Zhonghua Gan Zang Bing Za Zhi; 2007 Nov; 15(11):809-11. PubMed ID: 18073061
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis B virus reactivation following immunosuppressive therapy: guidelines for prevention and management.
Lubel JS; Testro AG; Angus PW
Intern Med J; 2007 Oct; 37(10):705-12. PubMed ID: 17894766
[TBL] [Abstract][Full Text] [Related]
16. Prevention of hepatitis B reactivation with lamivudine in hepatitis B virus carriers with hematologic malignancies treated with chemotherapy--a prospective case series.
Vassiliadis T; Garipidou V; Tziomalos K; Perifanis V; Giouleme O; Vakalopoulou S
Am J Hematol; 2005 Nov; 80(3):197-203. PubMed ID: 16247746
[TBL] [Abstract][Full Text] [Related]
17. Evidence for the insufficient evaluation and undertreatment of chronic hepatitis B infection in a predominantly low-income and immigrant population.
Jung CW; Tan J; Tan N; Kuo MN; Ashok A; Eells SJ; Miller LG
J Gastroenterol Hepatol; 2010 Feb; 25(2):369-75. PubMed ID: 19929923
[TBL] [Abstract][Full Text] [Related]
18. [Effect of lamivudine for hepatitis B virus reactivation in blood cancer patients undergoing immunosuppressive chemotherapy].
Sugimoto R; Enjoji M; Kotoh K; Noguchi K; Tsuruta S; Nakamuta M; Nawata H
Fukuoka Igaku Zasshi; 2004 Oct; 95(10):274-9. PubMed ID: 15678886
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration.
Dai MS; Wu PF; Shyu RY; Lu JJ; Chao TY
Liver Int; 2004 Dec; 24(6):540-6. PubMed ID: 15566502
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis B virus infection who are receiving chemoimmunotherapy.
Koo YX; Tan DS; Tan IB; Tao M; Chow WC; Lim ST
Cancer; 2010 Jan; 116(1):115-21. PubMed ID: 19899164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
